keyword
MENU ▼
Read by QxMD icon Read
search

No melanoma

keyword
https://www.readbyqxmd.com/read/28346253/a-retrospective-case-matched-cost-comparison-of-surgical-treatment-of-melanoma-and-nonmelanoma-skin-cancer-in-the-outpatient-versus-operating-room-setting
#1
Ryan P Johnson, Niraj Butala, Murad Alam, Naomi Lawrence
BACKGROUND: To date, no study has used authentic billing data in a case-control matched fashion to examine the cost of treating skin cancer in different settings. OBJECTIVE: To compare the cost of surgical treatment of skin cancer in the outpatient versus operating room setting using matched cases based on patient and skin cancer characteristics. METHODS: ICD-9 diagnosis codes for skin cancers were used to find patients who had a malignant excision current procedural terminology code in the operating room setting during 2010 to 2014...
March 23, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28345133/second-primary-melanoma-on-a-patient-undergoing-vemurafenib-therapy-a-case-report
#2
Giuliana Onnis, Giuseppe Palmieri, Maria Antonietta Montesu, Rosanna Satta
BACKGROUND: Several side effects have been reported during treatment with vemurafenib, including multiple benign lesions and, less frequently, atypical melanocytic proliferations and second primary melanomas. METHODS: A 46-year-old man undergoing vemurafenib therapy for metastatic malignant melanoma was clinically and dermoscopically monitored using total-body mapping. RESULTS: During BRAF inhibitor (BRAFi) treatment, the patient developed atypical melanocytic lesions and particularly secondary primary melanoma...
March 26, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28343447/the-undifferentiated-carcinoma-that-became-a-melanoma-re-biopsy-of-a-cancer-of-an-unknown-primary-site-a-case-report
#3
Oluf Dimitri Røe, Sissel Gyrid Freim Wahl
BACKGROUND: Cancer of unknown primary site is still a demanding condition as it is per definition metastatic, with heterogeneous biological behavior, and it is often resistant to therapy. Cancer of unknown primary site accounts for approximately 1 to 5 % of all cancers, but is currently among the top six causes of cancer deaths in Western countries. To correctly identify the biological origin of the tumor, a large spectrum of differential diagnoses must be considered and scrutinized. At progression, re-biopsy might be necessary to reveal the true origin of the tumor or actionable targets...
March 27, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28342269/acral-lentiginous-melanoma-versus-other-melanoma-a-single-center-analysis-in-japan
#4
Maiko Wada, Takamichi Ito, Gaku Tsuji, Takeshi Nakahara, Akihito Hagihara, Masutaka Furue, Hiroshi Uchi
We summarize herein our 14-year experience of conventional treatment outcomes before the era of molecular-targeted therapy and immunotherapy. Specifically, we conducted a retrospective review of our 252 patients with primary cutaneous melanoma (acral lentiginous melanoma [ALM], n = 121; non-acral lentiginous melanoma [non-ALM], n = 131), and compared the prognostic factors between ALM and non-ALM. Melanoma-specific survival and disease-free survival were estimated using the Kaplan-Meier method. Regarding the results, all patients were Japanese (106 male and 146 female), with a mean age of 60...
March 24, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28338667/primary-photodynamic-therapy-with-verteporfin-for-small-pigmented-posterior-pole-choroidal-melanoma
#5
I D Fabian, A W Stacey, V Papastefanou, L Al Harby, A K Arora, M S Sagoo, V M L Cohen
PurposeThe purpose of the study was to investigate the outcomes of primary photodynamic therapy (PDT) for small pigmented posterior pole choroidal melanoma.Patients and methodsProspective interventional consecutive case series of 15 patients with small pigmented posterior pole choroidal melanoma, who were treated with three sessions of PDT and followed-up thereafter. Risk factors for failure were assessed and outcome measures at presentation were compared to those at last follow-up visit.ResultsTumor control was achieved in 12 (80%) patients in a median follow-up time of 15 months (mean 14, range 8-18)...
March 24, 2017: Eye
https://www.readbyqxmd.com/read/28338441/radiosurgery-in-the-management-of-brain-metastasis-a-retrospective-single-center-study-comparing-gamma-knife-and-linac-treatment
#6
Constantin Tuleasca, Laura Negretti, Mohamed Faouzi, Vera Magaddino, Thierry Gevaert, Erik von Elm, Marc Levivier
OBJECTIVE The authors present a retrospective analysis of a single-center experience with treatment of brain metastases using Gamma Knife (GK) and linear accelerator (LINAC)-based radiosurgery and compare the results. METHODS From July 2010 to July 2012, 63 patients with brain metastases were treated with radiosurgery. Among them, 28 (with 83 lesions) were treated with a GK unit and 35 (with 47 lesions) with a LINAC. The primary outcome was local progression-free survival (LPFS), evaluated on a per-lesion basis...
March 24, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28334439/a-phase-2-trial-of-dasatinib-in-patients-with-locally-advanced-or-stage-iv-mucosal-acral-or-vulvovaginal-melanoma-a-trial-of-the-ecog-acrin-cancer-research-group-e2607
#7
Kevin Kalinsky, Sandra Lee, Krista M Rubin, Donald P Lawrence, Anthony J Iafrarte, Darell R Borger, Kim A Margolin, Mario M Leitao, Ahmad A Tarhini, Henry B Koon, Andrew L Pecora, Anthony J Jaslowski, Gary I Cohen, Timothy M Kuzel, Christopher D Lao, John M Kirkwood
BACKGROUND: KIT-directed tyrosine kinase inhibitors such as imatinib have demonstrated benefits in KIT-mutant (KIT+) mucosal, acral, vulvovaginal, and chronically sun-damaged (CSD) melanoma. Dasatinib has superior preclinical activity in comparison with other tyrosine kinase inhibitors against cells with the most common KIT mutation, exon 11(L576P) . The ECOG-ACRIN E2607 trial assessed dasatinib in patients with these melanoma subtypes. METHODS: Patients received 70 mg of oral dasatinib twice daily...
March 23, 2017: Cancer
https://www.readbyqxmd.com/read/28332989/multicenter-study-of-carbon-ion-radiation-therapy-for-mucosal-melanoma-of-the-head-and-neck-subanalysis-of-the-japan-carbon-ion-radiation-oncology-study-group-j-cros-study-1402-hn
#8
Masashi Koto, Yusuke Demizu, Jun-Ichi Saitoh, Hiroaki Suefuji, Hiroshi Tsuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
PURPOSE: To evaluate the efficacy and safety of carbon-ion radiation therapy (RT) for mucosal melanoma of the head and neck (MMHN) in the Japan Carbon-Ion Radiation Oncology Study Group study. METHODS AND MATERIALS: Patients with MMHN with N0-1M0 status who were treated with carbon-ion RT at 4 institutions in Japan between November 2003 and December 2014 were analyzed retrospectively. Two hundred sixty patients (male, 111; female, 149; median age, 68 years) with histologically proven MMHN were enrolled...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28331853/melanomas-and-dysplastic-nevi-differ-in-epidermal-cd1c-dendritic-cell-count
#9
Grzegorz Dyduch, Katarzyna Ewa Tyrak, Anna Glajcar, Joanna Szpor, Magdalena Ulatowska-Białas, Krzysztof Okoń
Background. Dendritic cells could be involved in immune surveillance of highly immunogenic tumors such as melanoma. Their role in the progression melanocytic nevi to melanoma is however a matter of controversy. Methods. The number of dendritic cells within epidermis, in peritumoral zone, and within the lesion was counted on slides immunohistochemically stained for CD1a, CD1c, DC-LAMP, and DC-SIGN in 21 of dysplastic nevi, 27 in situ melanomas, and 21 invasive melanomas. Results. We found a significant difference in the density of intraepidermal CD1c+ cells between the examined lesions; the mean CD1c cell count was 7...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28331615/nuclear-irf-1-expression-as-a-mechanism-to-assess-capability-to-express-pd-l1-and-response-to-pd-1-therapy-in-metastatic-melanoma
#10
James W Smithy, Lauren M Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M Neumeister, Mario Sznol, Harriet M Kluger, David L Rimm
BACKGROUND: Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (PD-L1), highlighting the need for a more sensitive biomarker. We hypothesize that capacity to express PD-L1, as assessed by an assay for a PD-L1 transcription factor, interferon regulatory factor 1 (IRF-1), may better distinguish patients likely to benefit from anti-PD-1 immunotherapy...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28330284/in-vitro-evaluation-of-anti-proliferative-anti-inflammatory-and-pro-apoptotic-activities-of-the-methanolic-extracts-of-andrographis-nallamalayana-ellis-on-a375-and-b16f10-melanoma-cell-lines
#11
Guroji Purushotham, Yerukala Padma, Yusuf Nabiha, R R Venkata Raju
Natural plant products have been widely used in controlling cancer with fewer or no side effects and the use of plant extracts as complementary to synthetic medicine is gaining increased popularity. Members of Andrographis plants possess important medicinal properties. In the present study, anti-cancerous properties of Andrographis nallamalayana (AN) were tested on A375 and B16F10 skin melanoma cancer cell lines. The leaf extracts of AN significantly reduced the cell viability and cell survival of skin cancer cell lines, achieved by MTT assay and clonogenic assays, respectively...
December 2016: 3 Biotech
https://www.readbyqxmd.com/read/28329671/trends-of-skin-cancer-incidence-following-transplantation-in-the-united-states
#12
Sarah T Arron
BackgroundSkin cancer is the most common malignancy occurring after organ transplantation. Although previous research has reported an increased risk of skin cancer in solid organ transplant recipients (OTR), no study has estimated the post-transplant population-based incidence in the US. The objective of this study is to determine the incidence and evaluate the predictors of post-transplant skin cancer, including squamous cell carcinoma (SCC), melanoma (MM), and Merkel cell carcinoma (MCC) in a cohort of US OTR receiving a primary transplant in 2003 or 2008...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329663/prognostic-modeling-in-desmoplastic-melanoma-using-different-cutpoints-for-the-proportion-of-desmoplasia
#13
Michael E Ming, Adaobi I Nwaneshiudu, Xiao-Wei Xu, Giorgos C Karakousis, David E Elder, Rosalie Elenitsas
Currently, desmoplastic melanomas are commonly divided into "pure" desmoplastic melanoma (at least 90% desmoplasia histologically) and "mixed" (<90%), with pure having a better prognosis, but our understanding of the relationship between percent desmoplasia and prognosis is incomplete. We sought to determine whether a more refined grading system that examined extent of desmoplasia by percent in 10% increments would be a better prognostic model. We also sought to determine the optimal cutpoint for percent desmoplasia if a single cutpoint were used...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329657/perceptions-of-indoor-vs-outdoor-tanning-risks-among-melanoma-patients-who-have-a-history-of-indoor-uv-tanning-an-international-internet-survey
#14
Jennifer Nergard, Chauncey Caldwell, Morgan Barr, Robert P Dellavalle, James A Solomon
IntroductionA new U.S. FDA regulation categorizes tanning beds as category II¹, and similar global regulatory action require informing users of the "risk of skin cancer" as methods to reverse the growing trend of indoor tanning. However, little is known from the patient's perspective on whether or not knowledge of risk of cancer is a deterrent to indoor tanning. Also, there is conflicting literature on the relationship between frequency of indoor tanning, age of onset and characteristics of patients' melanoma diagnoses...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329632/cigarette-smoking-and-the-risks-of-incident-basal-cell-carcinoma-and-squamous-cell-carcinoma-in-a-large-population-based-cohort-study
#15
Jean Claude Dusingize, Catherine M Olsen, Nirmala Pandeya, Bridie Thompson, Rachel E Neale, Padmini Subramaniam, David C Whiteman, Adele C Green
Tobacco smoking is a strong risk factor for cancer, but associations with basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin have been inconsistent. We prospectively investigated the associations between cigarette smoking and 3-year incidence of first primary BCC or SCC in the QSkin cohort (n=43765). Smoking history was self-reported at baseline; newly diagnosed and surgically treated BCCs and SCCs were ascertained through linkage to the national health insurance scheme and verified by histopathology reports...
September 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329597/melanoma-occurrence-under-long-term-etanercept-treatment-for-psoriasis-a-case-report
#16
Laura Atzori, Luca Pilloni, Severino Murgia, Cristina Mugheddu, Monica Pau, Franco Rongioletti
Melanoma occurrence during treatment with anti-tumor necrosis factor is considered an incidental event, although very recent studies suggest a risk. Etanercept is a fusion protein that binds the tumor necrosis factor receptor and is included among TNF inhibitors, approved for the treatment of several autoimmune diseases, such as psoriasis.We described a 79-year-old man with psoriasis, being treated with etanercept, who presented with a new brown to black macule on his right shoulder; this was immediately surgically excised...
October 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28323902/no-prognostic-value-added-by-vitamin-d-pathway-snps-to-current-prognostic-system-for-melanoma-survival
#17
Li Luo, Irene Orlow, Peter A Kanetsky, Nancy E Thomas, Shenying Fang, Jeffrey E Lee, Marianne Berwick, Ji-Hyun Lee
The prognostic improvement attributed to genetic markers over current prognostic system has not been well studied for melanoma. The goal of this study is to evaluate the added prognostic value of Vitamin D Pathway (VitD) SNPs to currently known clinical and demographic factors such as age, sex, Breslow thickness, mitosis and ulceration (CDF). We utilized two large independent well-characterized melanoma studies: the Genes, Environment, and Melanoma (GEM) and MD Anderson studies, and performed variable selection of VitD pathway SNPs and CDF using Random Survival Forest (RSF) method in addition to Cox proportional hazards models...
2017: PloS One
https://www.readbyqxmd.com/read/28318130/blue-nevus-like-and-blue-nevus-associated-melanoma-a-comprehensive-review-of-the-literature
#18
REVIEW
Thore L Borgenvik, Tina M Karlsvik, Saikat Ray, Monica Fawzy, Nick James
BACKGROUND: Malignant blue nevus, blue nevus-associated melanoma and blue nevus-like melanoma are all terms used to describe malignant melanomas arising from, in association with, or resembling blue nevi. This review is aimed at summarizing the available literature to reduce the confusion surrounding this rare malignancy, and aid the surgeon in choosing further diagnostic or therapeutic measures. METHODS: We conducted a search of Medline, Embase, Science Direct, Scopus and the Cochrane Library for all full text articles published in English that reported on a malignant melanoma arising from, in association with, or resembling a blue nevus...
March 20, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28316007/talimogene-laherparepvec-for-treating-metastatic-melanoma-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#19
REVIEW
Nigel Fleeman, Adrian Bagust, Angela Boland, Sophie Beale, Marty Richardson, Ashma Krishan, Angela Stainthorpe, Ahmed Abdulla, Eleanor Kotas, Lindsay Banks, Miranda Payne
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Amgen) of talimogene laherparepvec (T-VEC) to submit clinical and cost-effectiveness evidence for previously untreated advanced (unresectable or metastatic) melanoma as part of the Institute's Single Technology Appraisal process. The Liverpool Reviews and Implementation Group (LRiG) at the University of Liverpool was commissioned to act as the Evidence Review Group (ERG). This article presents a summary of the company's submission of T-VEC, the ERG review and the resulting NICE guidance (TA410), issued in September 2016...
March 18, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28301624/photodynamic-therapy-effectively-treats-actinic-keratoses-without-pre-illumination-incubation-time
#20
Jessica Gandy, Brian Labadie, Dina Bierman, Christopher Zachary
<p>BACKGROUND: Actinic keratoses (AKs) are dysplastic lesions of the epidermis that have the potential to progress to non-melanoma skin cancers (NMSC). Traditional photodynamic therapy (PDT) requires a pre-illumination incubation time, which adds to overall in-office time and has been linked to pain. Our group has found a novel protocol to effectively treat AKs with PDT that eliminates the pre-illumination incubation period and uses 2 back-to-back cycles of 16 minute 40 seconds.</p> <p>METHODS: The patient was prepped with soapy water and isopropyl alcohol, and thick AKs were descaled with a curette...
March 1, 2017: Journal of Drugs in Dermatology: JDD
keyword
keyword
17846
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"